Discover
PF-06826647 / PfizerA Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis (clinicaltrials.gov) - Dec 24, 2019 - P2b; N=202; Not yet recruiting; Sponsor: Pfizerfilgotinib (GLPG0634) / GileadFilgotinib regulatory estimate: Approval for ulcerative colitis around mid-2020 (Barclays) - Dec 25, 2019 - A subscription to Thomson ONE is required to gain full access to report 68490284; Page no: 6, 1; REPORT TITLE: "Galapagos: Christmas comes early for GLPG holders - thoughts on the recent outperformance”; AUTHOR: Field, Emily, et al; DATE: 12/13/2019filgotinib (GLPG0634) / GileadGilead and Eisai enter into agreement in Japan for the co-promotion of the investigational rheumatoid arthritis therapy filgotinib, pending regulatory approval (Businesswire) - Dec 24, 2019 - "Gilead Sciences, Inc....and Eisai Co., Ltd....announced today that Gilead Sciences K.K. (Tokyo, Japan) and Eisai have entered into an agreement for the distribution and co-promotion of filgotinib...in Japan, pending regulatory approval for the treatment of rheumatoid arthritis (RA). Through this collaboration, Gilead Japan will retain responsibility for manufacturing and marketing approval of filgotinib, while Eisai will be responsible for product distribution in Japan in RA and other potential future indications. The companies will jointly commercialize the medicine if approved."PTG-200 / Protagonist Therapeutics, J&JPTG-200 regulatory estimate: Approval for Crohn’s disease in 2023 (BTIG) - Dec 25, 2019 - A subscription to Thomson ONE is required to gain full access to report 68441439; Page no: 7; REPORT TITLE: "Protagonist Therapeutics, Inc. - Sell off in shares on PTG-300 preliminary data in beta-thalassemia seems overdone”; AUTHOR: Chiang, Timothy, et al; DATE: 12/04/2019Entyvio (vedolizumab) / TakedaPhase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study (clinicaltrials.gov) - Dec 23, 2019 - P4; N=60; Suspended; Sponsor: Takeda; Trial completion date: Jul 2019 --> Aug 2020; Recruiting --> Suspended; Trial primary completion date: Jul 2019 --> Aug 2020Stelara (ustekinumab) / J&JSEAVUE: Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year (clinicaltrials.gov) - Dec 26, 2019 - P3b; N=384; Active, not recruiting; Sponsor: Janssen Scientific Affairs, LLC; Recruiting --> Active, not recruitingBBT-401 / Bridge Bio, Daewoong PharmaBridge Biotherapeutics announces China NMPA clearance of IND for BBT-401, a pellino-1 inhibitor for UC (PRNewswire) - Dec 26, 2019 - "Bridge Biotherapeutics Inc...announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) cleared the Investigational New Drug (IND) application submitted as of September 25, 2019 for BBT-401, a potent first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis (UC). Bridge Biotherapeutics plans to initiate a Phase I study of BBT-401 in Chinese subjects in May 2020...The study will include 30 healthy volunteers and is targeting to complete by end of 2020."Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKAXifaxan sales projection: $1.4B in 2019 (Guggenheim) - Dec 30, 2019 - A subscription to Thomson ONE is required to gain full access to report 68502576; Page no: 8; REPORT TITLE: "Bausch Health Companies Ltd- BHC (Buy) - BHC (Buy) - Hepatic encephalopathy (HE) deep dive ahead of phase 2 data”; AUTHOR: Research Department; DATE: 12/16/2019Entyvio (vedolizumab) / TakedaEntyvio sales projection: $4,425M by 2025 (GlobalData) - Dec 26, 2019 - A subscription to Thomson ONE is required to gain full access to report 67577535; Page no: 71; REPORT TITLE: "Takeda Pharmaceutical Co Ltd (4502) - Financial and strategic SWOT analysis review”; AUTHOR: Globaldata; DATE: 12/18/2019Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKAXifaxan patent protection: Until 2031 for soluble solid dispersion tablets (Guggenheim) - Dec 30, 2019 - A subscription to Thomson ONE is required to gain full access to report 68502576; Page no: 4; REPORT TITLE: "Bausch Health Companies Ltd- BHC (Buy) - Hepatic encephalopathy (HE) deep dive ahead of phase 2 data”; AUTHOR: Research Department; DATE: 12/16/2019
